Literature DB >> 34796404

Destabilization of the Alzheimer's amyloid-β peptide by a proline-rich β-sheet breaker peptide: a molecular dynamics simulation study.

Pavan Krishna Kanchi1, Ashok Kumar Dasmahapatra2,3.   

Abstract

The amyloid-β peptide exists in the form of fibrils in the plaques found in the brains of patients with Alzheimer's disease. One of the therapeutic strategies is the design of molecules which can destabilize these fibrils. We present a designed peptide KLVFFP5 with two segments: the self-recognition sequence KLVFF and a β-sheet breaker proline pentamer. Molecular dynamics simulations and docking results showed that this peptide could bind to the protofibrils and destabilize them by establishing hydrophobic contacts and hydrogen bonds with a higher affinity than the KLVFF peptide. In the presence of the KLVFFP5 peptide, the β-sheet content of the protofibrils was reduced significantly; the hydrogen bonding network and the salt bridges were disrupted to a greater extent than the KLVFF peptide. Our results indicate that the KLVFFP5 peptide is an effective β-sheet disruptor which can be considered in the therapy of Alzheimer's disease.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid-β fibril; KLVFF; Molecular dynamics simulations

Mesh:

Substances:

Year:  2021        PMID: 34796404     DOI: 10.1007/s00894-021-04968-x

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  71 in total

Review 1.  Shattuck lecture--neurodegenerative diseases and prions.

Authors:  S B Prusiner
Journal:  N Engl J Med       Date:  2001-05-17       Impact factor: 91.245

Review 2.  Alzheimer's disease: genes, proteins, and therapy.

Authors:  D J Selkoe
Journal:  Physiol Rev       Date:  2001-04       Impact factor: 37.312

3.  Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.

Authors:  Lars Lannfelt; Kaj Blennow; Henrik Zetterberg; Stellan Batsman; David Ames; John Harrison; Colin L Masters; Steve Targum; Ashley I Bush; Ross Murdoch; Janet Wilson; Craig W Ritchie
Journal:  Lancet Neurol       Date:  2008-07-30       Impact factor: 44.182

4.  Metal ion-dependent effects of clioquinol on the fibril growth of an amyloid {beta} peptide.

Authors:  Bakthisaran Raman; Tadato Ban; Kei-Ichi Yamaguchi; Miyo Sakai; Tomoji Kawai; Hironobu Naiki; Yuji Goto
Journal:  J Biol Chem       Date:  2005-02-16       Impact factor: 5.157

Review 5.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

6.  Semi-synthesis and biological evaluation of flavone hybrids as multifunctional agents for the potential treatment of Alzheimer's disease.

Authors:  Shaochun Shi; Huibin Wang; Jian Wang; Yvxi Wang; Xiaobian Xue; Zilin Hou; Guo-Dong Yao; Xiao-Xiao Huang; Hongwei Zhao; Qingbo Liu; Shao-Jiang Song
Journal:  Bioorg Chem       Date:  2020-05-12       Impact factor: 5.275

7.  Inhibition of Amyloid-β Aggregation by Cobalt(III) Schiff Base Complexes: A Computational and Experimental Approach.

Authors:  Aysenur Iscen; Christopher R Brue; Kaleigh F Roberts; Joy Kim; George C Schatz; Thomas J Meade
Journal:  J Am Chem Soc       Date:  2019-10-10       Impact factor: 15.419

8.  Hexahydropyrrolo[2,3-b]indole Compounds as Potential Therapeutics for Alzheimer's Disease.

Authors:  Deborah Doens; Mario E Valdés-Tresanco; Velmarini Vasquez; Maria Beatriz Carreira; Yila De La Guardia; David E Stephens; Viet D Nguyen; Vu T Nguyen; Jianhua Gu; Muralidhar L Hegde; Oleg V Larionov; Pedro A Valiente; Ricardo Lleonart; Patricia L Fernández
Journal:  ACS Chem Neurosci       Date:  2019-10-07       Impact factor: 4.418

Review 9.  Protein aggregation and neurodegenerative disease.

Authors:  Christopher A Ross; Michelle A Poirier
Journal:  Nat Med       Date:  2004-07       Impact factor: 53.440

10.  Platinum-based inhibitors of amyloid-beta as therapeutic agents for Alzheimer's disease.

Authors:  Kevin J Barnham; Vijaya B Kenche; Giuseppe D Ciccotosto; David P Smith; Deborah J Tew; Xiang Liu; Keyla Perez; Greg A Cranston; Timothy J Johanssen; Irene Volitakis; Ashley I Bush; Colin L Masters; Anthony R White; Jeffrey P Smith; Robert A Cherny; Roberto Cappai
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-07       Impact factor: 11.205

View more
  1 in total

1.  Consecutive Aromatic Residues Are Required for Improved Efficacy of β-Sheet Breakers.

Authors:  Adam Jarmuła; Monika Zubalska; Dariusz Stępkowski
Journal:  Int J Mol Sci       Date:  2022-05-08       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.